John McCaffrey

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.5K citations

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Mario Sznol, Pier Francesco Ferrucci, David Hogg et al. · Journal of Clinical Oncology · 2017 · 293 citations

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

John C. Araujo, Géralyn C. Trudel, Fred Saad et al. · The Lancet Oncology · 2013 · 229 citations · Full text

Double-blind Phase 3, Urology, Genitourinary Cancer +6

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Melanoma, Immunology +10

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Pirkko‐Liisa Kellokumpu‐Lehtinen, Ulrika Harmenberg, Timo Joensuu et al. · The Lancet Oncology · 2013 · 205 citations

Urology, Oncology, Genitourinary Cancer +5